AltrixBio is a biopharmaceutical company focused on developing innovative treatments for cardiometabolic diseases. The company's lead candidate, AJN 003 (LuCI™), is a first-in-class oral therapy designed to replicate the metabolic benefits of bariatric surgery without the associated risks, targeting type 2 diabetes, obesity, and other metabolic disorders. Founded in 2019, AltrixBio leverages research from Mass General Brigham and Harvard Medical School to create novel, patent-protected therapies aimed at transforming the treatment landscape for these conditions.
Leadership & Board
Current Number of Employees10
Current LinkedIn Followers854
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$5M
Total Amount Raised$5M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$5M
Latest Funding Amount$5M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
AltrixBio had 10 employees as of April 6, 2026. The number of employees increased by 0 (0.00%) week-over-week.
10Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
AltrixBio had 854 followers as of April 6, 2026. The number of followers increased by 3 (0.35%) week-over-week.
854Latest Followers Count
3(0.35%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.